b
r
c
r
c
l
e
n
f
keyword
anemia
red
blood
cell
transfus
restrict
vs
liber
transfus
practic
anemia
present
twothird
patient
malign
hematolog
disord
etiolog
anemia
predomin
ineffect
erythropoiesi
marrow
infiltr
cytokin
relat
suppress
erythropoietin
suppress
vitamin
defici
ineffect
erythropoiesi
exacerb
acceler
clearanc
due
antibodi
mediat
hemolysi
thrombot
microangiopathi
anemia
chronic
natur
symptom
gener
well
toler
often
nonspecif
transfus
red
blood
cell
rbc
balanc
provid
benefit
patient
avoid
risk
transfus
conservativerestrict
rbc
transfus
practic
shown
equival
patient
outcom
compar
liber
transfus
practic
metaanalysi
shown
improv
inhospit
mortal
reduc
cardiac
event
rebleed
bacteri
infect
implic
lower
threshold
transfus
patient
malign
therefor
increasingli
scrutin
altern
manag
strategi
anemia
iv
iron
erythropoietin
stimul
agent
esa
consid
appropri
set
blood
transfus
therapi
key
compon
support
care
adult
children
malign
hematolog
disord
leukemia
recipi
hematopoiet
stem
cell
transplant
hsct
twothird
patient
hematolog
malign
develop
anemia
highest
preval
children
leukemia
lymphoma
transfus
red
blood
cell
rbc
balanc
benefit
maintain
oxygen
deliveri
inher
risk
blood
transfus
previous
publish
review
blood
transfus
practic
adult
elderli
updat
blood
transfus
therapi
adult
children
summar
pathophysiolog
anemia
set
indic
red
blood
cell
rbc
transfus
current
blood
risk
special
situat
rbc
transfus
altern
adjunct
therapi
anemia
manag
erythropoiet
stimul
agent
esa
iron
therapi
possibl
provid
evidencebas
guidelin
best
practic
anemia
set
multifactori
includ
product
defect
acceler
clearanc
hemorrhag
caus
anemia
includ
leukem
infiltr
bone
marrow
diagnosi
relaps
chemotherapi
radiat
therapi
suppress
erythropoietin
respons
anemia
infectioninflamm
shorten
rbc
surviv
hemorrhag
secondari
thrombocytopenia
andor
consumpt
coagulopathi
dissemin
intravascular
coagul
anemia
patient
leukemia
often
due
underproduct
erythropoiet
precursor
direct
tumor
infiltr
bone
marrow
chemotherapi
patient
undergo
hsct
radiotherapi
prepar
myeloabl
chemotherapi
regimen
challeng
rbc
precursor
product
nineti
six
percent
adult
patient
receiv
myeloabl
chemotherapi
prepar
requir
rbc
support
compar
patient
receiv
nonmyeloabl
prepar
reduc
ineffect
erythropoiesi
form
renal
dysfunct
reduc
erythropoietin
cytokin
mediat
anemia
chronic
diseas
acd
also
contribut
anemia
patient
hematolog
malign
tumorreleas
cytokin
upregul
hepcidin
lead
sequestr
bodi
iron
store
bone
marrow
macrophag
reduc
iron
absorpt
alimentari
tract
hepcidin
degrad
ferroportin
receptor
respons
make
iron
avail
erythropoiesi
iron
transport
enterocyt
marrow
macrophag
plasma
red
cell
precursor
may
also
select
reduc
ie
pure
red
cell
aplasia
due
aboincompat
hst
underli
lymphoprolif
disord
certain
drug
format
antibodi
erythropoietin
less
frequent
contribut
caus
erythropoiesi
suppress
includ
viral
suppress
erythropoiesi
occur
blood
review
variou
infect
includ
parvoviru
renal
insuffici
vitamin
defici
iron
folat
vitamin
may
also
contribut
anemia
adult
patient
illustr
fig
shorten
rbc
surviv
also
accompani
anemia
underproduct
malign
lymphoprolif
condit
chronic
lymphocyt
leukemia
hodgkin
nonhodgkin
lymphoma
lymphoplasmacyt
lymphoma
associ
warm
cold
reactiv
autoantibodi
rbc
fludarabin
purin
analog
also
increas
frequenc
autoimmun
hemolyt
anemia
aha
laboratori
find
aha
typic
includ
low
hemoglobin
high
lactat
dehydrogenas
ldh
high
bilirubin
typic
indirect
low
haptoglobin
hemoglobinuria
posit
direct
antiglobulin
test
dat
igg
classic
warm
aha
complement
cold
aha
malign
target
therapi
also
associ
microangiopath
hemolyt
anemia
maha
dissemin
intravascular
coagul
dic
acut
dic
uncommon
present
hematolog
malign
urokinaselik
plasminogen
activ
found
blast
acut
promyelocyt
leukemia
apl
often
lead
dic
prior
widespread
treatment
alltran
retino
acid
chemotherapi
agent
cisplatin
bleomycin
daunorubicin
calcineurin
inhibitor
use
hsct
patient
cyclosporin
tacrolimu
shown
independ
lead
druginduc
maha
sign
symptom
anemia
vari
base
acuiti
anemia
compensatori
chang
blood
volum
compensatori
chang
patient
cardiovascular
system
chronic
anemia
gener
well
toler
due
compensatori
expans
intravascular
plasma
volum
increas
cardiac
output
vasodilat
increas
blood
flow
due
decreas
viscos
least
increas
rbc
diphosphoglycer
dpg
right
shift
oxygen
dissoci
curv
symptom
anemia
often
nonspecif
includ
fatigu
pallor
dizzi
headach
vertigo
tinnitu
dyspnea
fig
evalu
manag
anemia
blood
count
demonstr
anemia
evalu
begin
assess
iron
statu
ferritin
andor
iron
satur
level
indic
absolut
iron
defici
iron
therapi
indic
ferritin
andor
iron
satur
valu
rule
absolut
iron
defici
serum
creatinin
glomerular
filtrat
rate
gfr
determin
may
indic
chronic
kidney
diseas
ckd
ferritin
andor
iron
satur
valu
determin
evalu
rule
absolut
iron
defici
versu
inflammationchron
diseas
necessari
clinic
respons
therapeut
trial
iron
would
confirm
absolut
iron
defici
respons
iron
therapi
would
indic
anemia
chronic
diseas
suggest
esa
therapi
consid
reproduc
permiss
goodnough
lt
schrier
j
hematol
faint
inact
fatigu
specif
link
poor
qualiti
life
children
addit
experi
poor
feed
irrit
chang
behavior
poor
school
perform
cardiac
enlarg
evid
congest
heart
failur
may
present
bruit
flow
murmur
gallop
rhythm
sever
anemia
tradit
therapi
cancerrel
anemia
rbc
transfus
howev
blood
transfus
identifi
one
overus
inappropri
therapeut
intervent
nation
accredit
joint
commiss
medic
societi
american
board
intern
medicin
american
medic
associ
american
societi
hematolog
guidelin
publish
aabb
nation
cancer
center
network
nccn
rbc
transfus
therapi
well
altern
anemia
therapi
iv
iron
esa
therapi
addit
guidelin
specif
pediatr
adult
clinic
set
publish
review
transfusiontransmit
infect
prompt
concern
patient
healthcar
provid
sinc
recognit
transfusiontransmiss
hiv
hepat
c
viru
hcv
risk
decreas
substanti
respons
emerg
pathogen
transmit
blood
transfus
rapid
fig
transfusionrel
acut
lung
injuri
trali
caus
highest
percentag
fatal
report
fda
follow
hemolyt
transfus
reaction
caus
nonabo
abo
incompat
blood
transfus
rbc
transfus
associ
number
potenti
side
effect
includ
common
one
febril
nonhemolyt
mild
allerg
reaction
hla
rbc
antigen
alloimmun
bacteri
viral
infect
transmiss
transfus
associ
graft
vs
host
diseas
tagvhd
morbid
mortal
risk
associ
transfusiontransmit
cmv
infect
tagvhd
immunocompromis
patient
beyond
scope
review
interest
reader
advers
outcom
specif
immunocompromis
host
refer
relev
review
increas
evid
suggest
far
greater
number
patient
advers
clinic
outcom
increas
morbid
mortal
associ
unnecessari
blood
transfus
tabl
list
risk
includ
known
transmiss
pathogen
infecti
diseas
transfus
reaction
trali
error
blood
administr
circulatori
overload
also
potenti
yet
undefin
risk
immunomodul
eg
periop
infect
tumor
progress
unknown
risk
recentlyemerg
pathogen
new
variant
creutzfeldtjakob
diseas
potenti
risk
associ
storag
lesion
blood
transfus
patient
clinic
set
cardiac
surgeri
awar
blood
risk
cost
led
provid
institutionbas
initi
patient
blood
manag
adopt
guidelin
limit
use
blood
transfus
patient
blood
manag
encompass
evidencebas
approach
multidisciplinari
transfus
medicin
specialist
surgeon
anesthesiologist
critic
care
specialist
multiprofession
physician
nurs
pump
technologist
pharmacist
prevent
strategi
emphas
identifi
evalu
manag
anemia
medic
surgic
patient
use
pharmacolog
intervent
avoid
unnecessari
diagnost
test
minim
iatrogen
blood
loss
establish
clinic
practic
guidelin
blood
transfus
singl
random
prospect
multicent
trial
evalu
hemoglobin
trigger
children
perform
lacroix
et
al
studi
children
admit
pediatr
intens
care
unit
icu
center
four
countri
random
either
restrictivestrategi
group
hemoglobin
threshold
set
gdl
liberalstrategi
transfus
group
hemoglobin
threshold
set
gdl
author
found
restrict
strategi
result
decreas
number
rbc
transfus
without
increas
rate
new
progress
multiorgan
dysfunct
primari
outcom
studi
number
secondari
outcom
includ
sepsi
transfus
reaction
nosocomi
respiratori
infect
catheterrel
infect
advers
event
length
stay
icu
hospit
moral
differ
group
author
recommend
restrict
rbc
transfus
strategi
pediatr
patient
stabl
icu
random
trial
investig
hemoglobin
threshold
complet
underway
neonat
prematur
need
transfus
pint
studi
suggest
liber
rbc
transfus
benefici
neurocognit
outcom
prematur
infant
month
contrast
bell
random
clinic
trial
iowa
show
poorer
neurolog
outcom
year
followup
prematur
infant
transfus
liber
transfus
prematur
top
trial
underway
address
conflict
result
evid
robust
random
control
trial
otherwis
lack
children
hematolog
malign
lead
heterogen
practic
differ
center
among
patient
group
survey
pediatr
center
children
oncolog
group
center
use
transfus
trigger
hemoglobin
gdl
wherea
center
use
gdl
clinician
consid
rbc
transfus
children
prior
radiat
therapi
patient
famili
may
seek
altern
transfus
volunt
commun
blood
donor
due
concern
blood
safeti
direct
blood
donor
individu
usual
rel
friend
donat
blood
specif
patient
advanc
schedul
transfus
procedur
direct
donor
unit
safer
allogen
rbc
unit
similar
rate
infecti
diseas
marker
posit
compar
volunt
commun
donor
unit
control
first
time
blood
donor
statu
sever
potenti
risk
must
consid
biolog
famili
member
wish
serv
direct
donor
child
may
later
need
hematopoiet
stem
cell
transplant
famili
member
includ
trali
rbc
hla
alloimmun
risk
adequ
explain
famili
wish
proceed
direct
donat
addit
practition
must
discuss
cost
time
donat
special
need
patient
aborh
blood
type
compat
cmv
seroneg
statu
may
met
direct
donorfamili
member
cellular
blood
compon
blood
rel
irradi
prevent
tagvhd
standard
dose
rbc
therapi
children
ml
per
kg
child
actual
bodi
weight
infus
h
take
care
maxim
use
blood
unit
enter
hemoglobin
increas
gdl
ml
per
kg
pack
rbc
transfus
unit
store
addit
solut
rate
rbc
transfus
well
studi
children
practition
take
http
wwwchoosingwiselyorgdoctorpatientlistsamericansocietyofhematolog
consider
sever
anemia
onset
ongo
blood
loss
cardiovascular
health
tradit
children
gradual
onset
sever
anemia
transfus
slow
rate
ie
mlkgh
prevent
transfus
associ
circulatori
overload
taco
recent
random
clinic
trial
show
children
without
evid
cardiac
failur
sever
anemia
none
develop
sign
circulatori
overload
rbc
transfus
rate
mlkgh
mlkgh
children
evid
cardiac
failur
practition
transfus
slowli
prescrib
diuret
necessari
patient
receiv
palli
care
also
anemia
good
evid
best
transfus
practic
children
commonli
children
advanc
cancer
last
month
life
complain
fatigu
famili
report
signific
suffer
fatigu
caus
fatigu
multifactori
includ
physiolog
psycholog
situat
factor
includ
anemia
disrupt
sleep
studi
adult
shown
treatment
anemia
either
rbc
transfus
erythropoietin
reduc
fatigu
enhanc
qualiti
life
children
erythropoietin
improv
anemia
fail
improv
qualiti
life
studi
need
pediatr
palli
care
address
best
treatment
anemia
moder
anemia
associ
symptom
due
signific
compensatori
mechan
preserv
oxygen
transport
set
reduc
hb
import
physiolog
compensatori
mechan
includ
increas
blood
flow
due
decreas
blood
viscos
increas
oxygen
unload
tissu
due
increas
red
cell
diphosphoglycer
dpg
mainten
blood
volum
due
increas
plasma
volum
redistribut
blood
flow
symptomat
manifest
occur
hb
twothird
normal
ie
less
gdl
basal
cardiac
output
increas
anem
patient
manifest
clinic
symptom
increas
cardiac
work
histor
practic
correct
moder
anemia
red
blood
cell
transfus
order
treat
sign
symptom
transfus
blood
prophylact
subsequ
reflect
one
public
state
concentr
hemoglobin
less
gdl
wise
give
blood
transfus
oper
readjust
transfus
trigger
hb
gdl
somewhat
lower
threshold
accompani
realiz
popul
jehovah
wit
patient
declin
blood
transfus
religi
belief
morbid
mortal
occur
hemoglobin
low
data
jehovah
wit
patient
indic
critic
level
hemodilut
defin
point
oxygen
consumpt
vo
start
decreas
insuffici
oxygen
deliveri
achiev
hb
level
approxim
gdl
patient
known
cardiovascular
diseas
cvd
anem
postop
mortal
report
increas
significantli
compar
patient
known
cvd
manag
anemia
transfus
trigger
therefor
differ
patient
posthoc
analysi
one
studi
accompani
editori
observ
surviv
tend
decreas
patient
preexist
heart
diseas
restrict
transfus
strategi
group
suggest
critic
ill
patient
heart
vascular
diseas
may
benefit
higher
hb
previous
publish
clinic
practic
set
guidelin
conclud
presenc
coronari
arteri
diseas
like
constitut
import
factor
determin
patient
toler
low
hb
retrospect
analysi
elderli
patient
n
year
age
hospit
acut
myocardi
infarct
unit
state
found
blood
transfus
patient
whose
admiss
hematocrit
valu
less
associ
significantli
lower
mortal
rate
aggress
use
blood
transfus
manag
anemia
elderli
patient
cardiac
diseas
warrant
increas
number
control
random
trial
provid
level
evid
blood
transfus
practic
previou
systemat
review
literatur
year
identifi
trial
author
conclud
time
exist
evid
support
use
restrict
transfus
trigger
patient
free
seriou
cardiac
diseas
cochran
systemat
review
prospect
random
trial
compar
high
versu
low
hb
threshold
trial
involv
total
patient
author
found
low
hb
threshold
well
toler
red
blood
cell
transfus
reduc
ci
patient
random
low
hb
cohort
number
red
blood
cell
transfus
reduc
unit
ci
unit
low
hb
cohort
recent
metaanalysi
found
restrict
red
blood
cell
transfus
strategi
aim
allow
hemoglobin
concentr
low
gdl
reduc
cardiac
event
rebleed
bacteri
infect
mortal
six
key
random
clinic
trial
adult
patient
compar
restrict
vs
liber
rbc
transfus
strategi
variou
clinic
set
tabl
transfus
requir
critic
care
tricc
trial
found
intens
care
patient
could
toler
restrict
transfus
strategi
hb
rang
gdl
gdl
averag
well
patient
transfus
liber
hb
rang
gdl
gdl
averag
differ
day
mortal
rate
contrast
retrospect
studi
patient
consecut
admit
icu
found
admiss
hematocrit
absenc
transfus
associ
longterm
mortal
may
hematocrit
level
transfus
risk
benefit
imbal
revers
trac
transfus
requir
cardiac
surgeri
trial
larg
singl
center
studi
patient
random
receiv
either
restrict
hematocrit
n
liber
hematocrit
n
red
blood
cell
transfus
postop
thirti
day
allcaus
mortal
differ
vs
respect
two
cohort
focu
trial
found
elderli
mean
year
age
patient
underw
repair
hip
fractur
surgeri
toler
hb
trigger
without
red
blood
cell
transfus
postop
low
gdl
higher
transfus
symptomat
recent
singl
center
prospect
studi
patient
upper
gastrointestin
ugi
bleed
demonstr
patient
random
restrict
hb
b
gdl
vs
liber
hb
b
gdl
hb
threshold
blood
transfus
significantli
improv
outcom
includ
mortal
day
rate
rebleed
mint
trial
pilot
feasibl
studi
liber
hemoglobin
gdl
versu
restrict
hemoglobin
b
gdl
transfus
threshold
initi
plan
enrol
patient
symptomat
coronari
arteri
diseas
acut
coronari
syndrom
stabl
angina
undergo
cardiac
catheter
termin
end
month
enrol
patient
elig
screen
patient
enrol
tabl
primari
composit
outcom
death
myocardi
infarct
revascular
occur
liber
transfus
cohort
compar
restrict
cohort
p
mortal
occur
respect
p
mint
trial
provid
evid
liber
transfus
practic
maintain
hemoglobin
threshold
gdl
repres
prudent
manag
high
risk
patient
symptomat
coronari
arteri
diseas
final
recent
publish
trial
lower
b
gdl
vs
higher
b
gdl
hemoglobin
threshold
transfus
patient
septic
shock
found
equival
day
mortal
vs
respect
patient
two
cohort
one
import
limit
prospect
random
clinic
trial
patient
elig
agre
particip
studi
may
particularli
reflect
patient
clinic
set
patient
determin
elig
tricc
trial
patient
elig
focu
trial
actual
enrol
studi
lead
concern
select
bia
treat
physician
accur
predict
patient
would
surviv
studi
enrol
other
therebi
ensur
differ
surviv
outcom
would
found
treatment
group
anoth
limit
interpret
transfus
trigger
studi
mean
pretransfus
hb
patient
restrict
red
cell
transfus
arm
trac
trial
gdl
tabl
similarli
mean
hb
patient
restrict
arm
tricc
trial
gdl
yet
interpret
studi
advoc
hb
gdl
appropri
use
transfus
trigger
critic
care
patient
number
publish
clinic
practic
guidelin
red
blood
cell
transfus
attest
increas
interest
import
appropri
blood
util
profession
societi
health
care
institut
tabl
select
discret
hb
trigger
rbc
transfus
controversi
guidelin
gener
acknowledg
necess
consid
patient
covari
patientspecif
criteria
make
transfus
decis
among
publish
guidelin
gener
agre
transfus
benefit
hb
greater
gdl
may
benefici
hb
less
gdl
editori
recent
summar
implic
trial
metaanalys
call
target
hb
level
transfus
state
longer
accept
recommend
transfus
use
vagu
approach
clinic
judgment
hope
allevi
symptom
howev
approach
would
use
transfus
treat
laboratori
number
rather
patient
would
risk
overinterpret
avail
evid
transfus
trigger
risk
underestim
heterogen
anemia
eg
acut
versu
chronic
heterogen
patient
ie
comorbid
given
increas
evid
show
blood
transfus
poorli
effect
possibl
harm
guid
principl
transfus
therapi
less
aabb
recent
publish
recommend
american
board
intern
medicin
choos
wise
campaign
advoc
singl
unit
rbc
transfus
nonbleed
hospit
patient
addit
unit
prescrib
reassess
patient
pediatr
adult
hospit
stanford
univers
medic
center
reduc
blood
use
use
computer
physician
order
entri
process
blood
transfus
hemoglobin
concentr
threshold
blood
transfus
decreas
clinic
effect
team
institut
physician
educ
clinic
decis
support
juli
via
best
practic
alert
bpa
time
electron
physician
order
entri
poe
fig
show
subsequ
analysi
trend
blood
use
stanford
health
center
shc
overal
blood
compon
transfus
increas
yearli
bpa
implement
juli
howev
rbc
transfus
decreas
importantli
interv
clinic
patient
outcom
length
stay
day
readmiss
rate
mortal
associ
hospitalwid
particularli
medic
surgic
patient
receiv
rbc
transfus
support
follow
clinic
decis
support
cd
restrict
transfus
practic
special
consider
transfus
red
blood
cell
adjunct
altern
therapi
erythropoietin
simul
agent
esa
iron
therapi
hemoglobin
threshold
transfus
rbc
consid
adjunct
therapi
erythropoiet
stimul
agent
esa
individu
differ
patient
toler
vari
degre
anemia
differ
even
moder
chronic
anemia
well
toler
patient
interv
increas
hemoglobin
lead
decreas
fatigu
improv
qualiti
life
adult
esa
consid
safe
therapeut
option
improv
function
statu
shown
reduc
transfus
requir
improv
respons
earli
howev
studi
began
show
esa
therapi
experiment
trial
design
target
normal
highnorm
hemoglobin
level
link
tumor
progress
shorten
surviv
later
trial
fail
confirm
detriment
effect
potenti
show
surviv
benefit
larg
metaanalysi
conclud
esa
therapi
increas
baselin
rate
thrombosi
present
cancer
patient
use
esa
versu
rbc
transfus
select
cancer
patient
chronic
kidney
diseas
palli
treatment
continu
fda
risk
evalu
mitig
strategi
current
risk
mitig
strategi
includ
use
esa
therapi
patient
hemoglobin
less
gdl
anemia
treat
higher
hgb
level
avail
altern
rbc
safer
optim
iron
statu
consid
prior
esa
treatment
simultan
iron
work
synergist
esa
achiev
optim
biolog
respons
increas
bioavail
iron
erythropoiesi
illustr
fig
nccn
guidelin
recommend
iron
therapi
independ
esa
absolut
ida
ferritin
b
ngml
transfus
satur
b
benefit
iron
alon
function
ida
ferritin
ngml
transfus
satur
benefit
combin
iron
esa
children
random
studi
use
esa
prevent
treat
cancer
associ
anemia
studi
difficult
interpret
given
small
patient
cohort
variabl
patient
popul
variabl
studi
design
treatment
dose
shankar
review
nine
random
trial
pediatr
conclud
role
esa
treatment
prevent
anemia
children
cancer
remain
unclear
exist
pediatr
data
suggest
use
esa
significantli
decreas
need
rbc
transfus
side
effect
mild
howev
data
show
improv
qualiti
life
costeffect
esa
potenti
role
promot
cancer
cell
growth
remain
signific
concern
children
level
evid
metaanalysi
studi
compar
restrict
vs
liber
transfus
practic
demonstr
clinic
patient
outcom
improv
fewer
red
cell
transfus
administ
futur
research
need
optim
manag
anemia
patient
seriou
comorbid
cardiac
diseas
whether
fresh
blood
associ
better
clinic
outcom
store
blood
ns
ja
state
conflict
interest
ltg
consult
american
regent
anemia
common
patient
hematolog
malign
multifactori
etiolog
level
evid
transfus
trigger
base
hemoglobin
level
move
restrict
liber
strategi
rbc
transfus
unlik
benefit
hb
greater
gdl
may
benefici
hb
less
gdl
treatment
moder
anemia
shown
improv
qualiti
life
benefici
effect
clinic
patient
outcom
unknown
iron
restrict
erythropoiesi
identifi
treat
erythropoietin
stimul
agent
use
cautious
adult
hematolog
malign
accord
fda
box
warn
label
rem
program
random
control
trail
restrict
versu
liber
rbc
transfus
compar
outcom
hematologyoncolog
popul
particularli
pediatr
safeti
profil
esa
use
differ
subset
oncolog
patient
select
patient
may
biggest
improv
qualiti
life
qol
investig
one
highest
qol
chang
identifi
improv
clinic
patient
outcom
